AI could predict which eye treatments work best for Diabetes-Related vision loss

NCT ID NCT07707856

Completed Knowledge-focused Sponsor: Benha University Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study reviews published research on artificial intelligence models that analyze retinal images to predict how well patients with diabetic macular edema will respond to treatments like anti-VEGF injections or laser therapy. By evaluating the accuracy of these AI tools, the review aims to identify the most promising imaging biomarkers and methods. The goal is to help doctors choose the right treatment for each patient, reducing vision loss and improving outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this review could identify reliable AI tools to personalize DME treatment, improving vision outcomes and reducing trial-and-error in therapy selection.
What could go wrong: As a systematic review of existing studies, it does not test new treatments directly. The findings depend on the quality and consistency of the included research, which may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates